Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 3/20 | 0.42 |
| ▸ | RHEB | Q15382 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31518358 | 1.00 | LTA4H (0.55) | LTA4HALDH1A1HTTMAPK1L3MBTL1 | |
| SCHEMBL16890039 | 0.86 | LTA4H (0.50) | LTA4HALDH1A1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL17472498 | 0.85 | LTA4H (0.55) | LTA4HALDH1A1HTTMAPK1L3MBTL1 | |
| SCHEMBL11646840 | 0.82 | LTA4H (0.61) | LTA4HALDH1A1HTTMAPK1L3MBTL1 | |
| SCHEMBL2099937 | 0.81 | ALDH1A1 (0.63) | LTA4HALDH1A1HTTMAPK1L3MBTL1 | |
| SCHEMBL1128891 | 0.81 | LTA4H (0.59) | LTA4HHTTL3MBTL1SMN1; SMN2TSHR | |
| SCHEMBL29558143 | 0.80 | CA12 (0.62) | ALDH1A1MEN1KMT2A | |
| SCHEMBL167090 | 0.80 | CA12 (0.62) | ALDH1A1MEN1KMT2A | |
| SCHEMBL14127541 | 0.80 | CA12 (0.62) | ALDH1A1MEN1KMT2A | |
| SCHEMBL5472622 | 0.80 | AR (0.53) | MAPK1KDM4EMEN1KMT2AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2283020-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009143051-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20050038019-A1 | Hydroxy substituted amides for the treatment of alzheimer's disease | PHARMACIA & UPJOHN | 2005-02-17 | — | — | US | disclosed |
| EP-1443923-A1 | HYDROXY SUBSTITUTED AMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003037325-A1 | HYDROXY SUBSTITUTED AMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| CN-1390219-A | Pyrazolopyrimidines as therapeutic agents | ABBOTT AG (DE) | 2003-01-08 | — | — | CN | disclosed |
| US-5747540-A | ENZYME INHIBITORS HYDROXY INDOLEAMIDES, COUMARIN AMIDES AND ISOTHIOCOUMARIN AMIDES | MERCK & CO., INC. (US) | 1998-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038019-A1 | Hydroxy substituted amides for the treatment of alzheimer's disease | BACE1, APP, BACE2 | LTA4H 410/4885ALDH1A1 554/4885HTT 26/4885 |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | LTA4H 4152/4885ALDH1A1 292/4885HTT 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.